These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 23013051)

  • 21. FDA issues Unique Device Identification final rule.
    Mathias JM
    OR Manager; 2013 Nov; 29(11):5, 26. PubMed ID: 24298669
    [No Abstract]   [Full Text] [Related]  

  • 22. Medical device regulation in the United States and the European Union: a comparative study.
    Chai JY
    Food Drug Law J; 2000; 55(1):57-80. PubMed ID: 12296349
    [No Abstract]   [Full Text] [Related]  

  • 23. FDA marketing claims, and the practitioner.
    Runner S
    J Evid Based Dent Pract; 2006 Mar; 6(1):19-23. PubMed ID: 17138391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Accounting for "lost pleasure" in a cost-benefit analysis of government regulation: the case of the Food and Drug Administration's proposed cigarette labeling regulation.
    Chaloupka FJ; Gruber J; Warner KE
    Ann Intern Med; 2015 Jan; 162(1):64-5. PubMed ID: 25322210
    [No Abstract]   [Full Text] [Related]  

  • 25. Medical device warning letter draft pilot; availability--FDA. Notice.
    Fed Regist; 1998 Aug; 63(166):45821-5. PubMed ID: 10182695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug-eluting stents will carry a warning.
    Expert Rev Med Devices; 2007 Jan; 4(1):9. PubMed ID: 17187475
    [No Abstract]   [Full Text] [Related]  

  • 27. Drug-review deadlines and safety problems.
    Nardinelli C; Lanthier M; Temple R
    N Engl J Med; 2008 Jul; 359(1):95-6; author reply 96-8. PubMed ID: 18596282
    [No Abstract]   [Full Text] [Related]  

  • 28. Further amendments to general regulations of the Food and Drug Administration to incorporate tobacco products. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2012 Feb; 77(22):5171-6. PubMed ID: 22359802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. US and European postmarket clinical data requirements.
    Donawa M
    Med Device Technol; 2005 Mar; 16(2):19-21. PubMed ID: 15828495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Science and regulation. FDA's approach to regulation of products of nanotechnology.
    Hamburg MA
    Science; 2012 Apr; 336(6079):299-300. PubMed ID: 22517845
    [No Abstract]   [Full Text] [Related]  

  • 31. Legal overprotection.
    Friedman JH
    Med Health R I; 2004 Oct; 87(10):294. PubMed ID: 15559378
    [No Abstract]   [Full Text] [Related]  

  • 32. Off-label use of medical devices in radiology: regulatory standards and recent developments.
    Smith JJ
    J Am Coll Radiol; 2010; 7(2):115-9. PubMed ID: 20142085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dietary supplement adverse event reports: review and analysis.
    Talati AR; Gurnani AK
    Food Drug Law J; 2009; 64(3):503-13. PubMed ID: 19999641
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Science and regulation. Regulating direct-to-consumer personal genome testing.
    McGuire AL; Evans BJ; Caulfield T; Burke W
    Science; 2010 Oct; 330(6001):181-2. PubMed ID: 20929761
    [No Abstract]   [Full Text] [Related]  

  • 35. The saga of Poly Implant Prosthese breast implants.
    Heneghan C
    BMJ; 2012 Jan; 344():e306. PubMed ID: 22236799
    [No Abstract]   [Full Text] [Related]  

  • 36. Medical device regulatory landscape: the imperative of finding balance.
    Kaplan AV; Williams DO
    Circ Cardiovasc Interv; 2012 Feb; 5(1):2-5. PubMed ID: 22337999
    [No Abstract]   [Full Text] [Related]  

  • 37. Impossible? Outlawing state safety laws for generic drugs.
    Glantz LH; Annas GJ
    N Engl J Med; 2011 Aug; 365(8):681-3. PubMed ID: 21830958
    [No Abstract]   [Full Text] [Related]  

  • 38. "It's time to make a good agency better": the Food and Drug Administration Modernization Act of 1997 and the First Amendment.
    Murphy AM
    Food Drug Law J; 1998; 53(4):603-25. PubMed ID: 10557579
    [No Abstract]   [Full Text] [Related]  

  • 39. Analysis and recommendations for agency action regarding nonsteroidal antiinflammatory drugs and cardiovascular risk.
    U.S. Food and Drug Administration
    J Pain Palliat Care Pharmacother; 2005; 19(4):83-97. PubMed ID: 16431839
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Shifting terrain in the regulation of off-label promotion of pharmaceuticals.
    Mello MM; Studdert DM; Brennan TA
    N Engl J Med; 2009 Apr; 360(15):1557-66. PubMed ID: 19357413
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.